Hansa Biopharma (HNSA) investor relations material

Strategic and financial highlights

• Out-licensing agreement in Europe with Cerba Pharma brings €110M upfront, strengthening cash position and focusing resources on U.S. pre-commercial and pipeline activities.

• Additional milestone payment expected upon EMA filing acceptance, targeted for Q4 2026, with Cerba taking over European clinical trials and commercial infrastructure, reducing costs.

• U.S. BLA for imlifidase under FDA review with a PDUFA date of December 19; conditional approval already in place in Europe as IDEFIRIX.

• Launch preparations in the U.S. are underway, targeting high-volume transplant centers and leveraging positive market research feedback.

• Market opportunity estimated at SEK 2 billion in the U.S., with reimbursement strategies including DRG codes, outlier payments, and NTAP application.

Clinical development and data

• European PAES study showed 90% graft failure-free survival, 98% patient survival, and 92% graft survival at one year in highly sensitized kidney transplant patients treated with imlifidase.

• U.S. phase III ConfIdeS trial demonstrated statistically and clinically significant improvement in eGFR at one year (51.5 vs. 19.3 mL/min) and higher transplant rates for imlifidase vs. control.

• Safety profile consistent with prior experience; no new safety signals, and adverse events were manageable.

• Real-world French registry data confirm high efficacy and safety, with 96% patient survival and robust kidney function at one year, even in patients with extreme sensitization.

• Predictable antibody reduction and manageable rebound enable effective post-transplant monitoring and intervention.

Market and medical impact

• Imlifidase addresses a critical unmet need for highly sensitized patients, many of whom are young, non-white, and female, often waiting years on dialysis with little hope for transplant.

• The therapy is seen as a game-changer, offering predictable, reliable desensitization and expanding transplant opportunities, including potential for living donor and other organ transplants.

• U.S. transplant centers show high interest, with early adoption expected in experienced, high-volume centers and broader uptake as protocols adapt.

• Pipeline includes gene therapy collaborations and a next-generation IgG-cleaving enzyme (HNSA-5487) targeting Guillain-Barré syndrome, with clinical trials planned.

• Manufacturing capacity in Europe is sufficient to support U.S. launch.